Glenmark Pharmaceuticals Ltd.

GLENMARK · NSE

Public Market Listing

GLENMARKNSE

NSE primary exchange listing

Live quotes, historical charts, and market capitalization for Glenmark Pharmaceuticals Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
3Phase 3 / Filed
0Phase 1–2 / Early
8Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 3
PD-L1Monoclonal antibody
HIVNon-Small Cell Lung CancerChronic Hepatitis BEndometrial Cancer
Phase 3
HER2Antibody–drug conjugate
Non-Small Cell Lung CancerBreast CancerOvarian CancerColorectal CancerGastric Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer

Upcoming events

(25 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (1)
Trastuzumab rezetecanPhase 1/2HER2-expressing Advanced Solid Tumors
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
December 2026 (6)
EnvafolimabPhase 1/2Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
Est. primary completion 2026-12 · NCT05024214 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 1/2Advanced Non-small Cell Lung Cancer
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 1/2Ovarian Cancer
Est. primary completion 2026-12 · NCT06840002 · CT.gov ↗
What to watch
EnvafolimabPhase 2Advanced Endometrial Cancer
Est. primary completion 2026-12 · NCT05112991 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 2HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Est. primary completion 2026-12-31 · NCT06413745 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 3HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Est. primary completion 2026-12-31 · NCT05424835 · CT.gov ↗
What to watch
2027 (8)
May 2027 (1)
Trastuzumab rezetecanPhase 3Ovarian Cancer
Est. primary completion 2027-05 · NCT06828354 · CT.gov ↗
What to watch
June 2027 (1)
Trastuzumab rezetecanPhase 3HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-06-30 · NCT06123494 · CT.gov ↗
What to watch
August 2027 (1)
EnvafolimabPhase 2Solid Tumor
Est. primary completion 2027-08-30 · NCT04891198 · CT.gov ↗
What to watch
October 2027 (1)
Trastuzumab rezetecanPhase 1/2Solid Tumor
Est. primary completion 2027-10 · NCT07140393 · CT.gov ↗
What to watch
December 2027 (4)
Trastuzumab rezetecanPhase 2HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-12 · NCT05671822 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 2Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-12 · NCT07102901 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 3Early-stage or Locally Advanced HER2-positive Breast Cancer
Est. primary completion 2027-12 · NCT07196774 · CT.gov ↗
What to watch
EnvafolimabPhase 3Non-small Cell Lung Cancer
Est. primary completion 2027-12-30 · NCT06123754 · CT.gov ↗
What to watch
2028 (4)
March 2028 (1)
Trastuzumab rezetecanPhase 3PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Est. primary completion 2028-03 · NCT07111832 · CT.gov ↗
What to watch
May 2028 (1)
Trastuzumab rezetecanPhase 2Advanced Colorectal Cancer Expressing HER2
Est. primary completion 2028-05-01 · NCT07796763 · CT.gov ↗
What to watch
June 2028 (2)
Trastuzumab rezetecanPhase 2HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Est. primary completion 2028-06 · NCT06778031 · CT.gov ↗
What to watch
Trastuzumab rezetecanPhase 2Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer
Est. primary completion 2028-06 · NCT07497386 · CT.gov ↗
What to watch
2029 (2)
June 2029 (1)
EnvafolimabPhase 2Biliary Tract Neoplasms
Est. primary completion 2029-06 · NCT04910386 · CT.gov ↗
What to watch
September 2029 (1)
Trastuzumab rezetecanPhase 3Advanced Colorectal Cancer
Est. primary completion 2029-09 · NCT07676162 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Trastuzumab rezetecanPhase 3HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Est. primary completion 2030-04 · NCT06126640 · CT.gov ↗
What to watch
October 2030 (1)
Trastuzumab rezetecanPhase 3Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2030-10 · NCT07118527 · CT.gov ↗
What to watch
December 2030 (1)
Trastuzumab rezetecanPhase 3Triple Negative Breast Cancer
Est. primary completion 2030-12 · NCT07679360 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Trastuzumab rezetecanPhase 3Non Small Cell Lung Cancer
Est. primary completion 2031-02 · NCT07896005 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 July 2026Filing acceptedTrastuzumab rezetecanNMPA accepts the marketing application for trastuzumab rezetecan in HER2-low breast cancer (CXSS2600103), with priority review
China, NMPA · Jiangsu Hengrui Pharmaceuticals · Source ↗

Financial reports

No financial reports recorded.